Clinical trialsCompany release

Allarity extends Phase 2 stenoparib ovarian cancer trial to platinum-refractory and non-RECIST patients

🇺🇸 Allarity Therapeutics, Inc. (ALLR) · Tue 17 Nov 2026

Allarity Therapeutics has amended its Phase 2 study of oral PARP/tankyrase inhibitor stenoparib in advanced ovarian cancer, adding two new patient groups evaluated separately from the original cohort.

Allarity Therapeutics announced on 16 November 2026 that it has amended its ongoing Phase 2 trial of stenoparib in advanced ovarian cancer. The drug is an oral dual inhibitor of PARP and tankyrase.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Allarity Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Allarity Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.